Precision BioLogic Leads the Way in Hemophilia Testing

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Precision-BioLogic

More Like This

PR Newswire associated0

Innovation Through Collaboration Puts Precision BioLogic on the Map in Hemostasis Diagnostics and Research

From left: Dr. Kitazawa, Dr. Hattori, and Dr. Igawa

Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors

PR Newswire associated0

Precision BioLogic Acquires George King Bio-Medical

PR Newswire associated0

Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors

PR Newswire associated0

Octapharma AG: Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products

Roche launches three new Factor Xa inhibitor coagulation tests to meet growing patient need

PR Newswire associated0

Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

PR Newswire associated0

Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026